We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The platform showed a sensitivity of more than 98 percent in finding the extent of cancer in patients who have intermediate-risk disease — the most frequently treated form of prostate cancer. Read More
Data from a post-approval study supported an updated indication for patients “without the presence of profound shock, end organ failure or acute neurologic injury,” the agency said. Read More